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Abstract
Psoriasis is a common inflammatory skin disease characterized by thickened scaly red plaques. Previously we have
performed a genome-wide association study (GWAS) on psoriasis with 1,359 cases and 1,400 controls, which were
genotyped for 447,249 SNPs. The most significant finding was for SNP rs12191877, which is in tight linkage disequilibrium
with HLA-Cw*0602, the consensus risk allele for psoriasis. However, it is not known whether there are other psoriasis loci
within the MHC in addition to HLA-C. In the present study, we searched for additional susceptibility loci within the human
leukocyte antigen (HLA) region through in-depth analyses of the GWAS data; then, we followed up our findings in an
independent Han Chinese 1,139 psoriasis cases and 1,132 controls. Using the phased CEPH dataset as a reference, we
imputed the HLA-Cw*0602 in all samples with high accuracy. The association of the imputed HLA-Cw*0602 dosage with
disease was much stronger than that of the most significantly associated SNP, rs12191877. Adjusting for HLA-Cw*0602, there
were two remaining association signals: one demonstrated by rs2073048 (p=2610
26, OR=0.66), located within c6orf10,a
potential downstream effecter of TNF-alpha, and one indicated by rs13437088 (p=9610
26, OR=1.3), located 30 kb
centromeric of HLA-B and 16 kb telomeric of MICA. When HLA-Cw*0602, rs2073048, and rs13437088 were all included in a
logistic regression model, each of them was significantly associated with disease (p=3610
247,6 610
28, and 3610
27,
respectively). Both putative loci were also significantly associated in the Han Chinese samples after controlling for the
imputed HLA-Cw*0602. A detailed analysis of HLA-B in both populations demonstrated that HLA-B*57 was associated with an
increased risk of psoriasis and HLA-B*40 a decreased risk, independently of HLA-Cw*0602 and the C6orf10 locus, suggesting
the potential pathogenic involvement of HLA-B. These results demonstrate that there are at least two additional loci within
the MHC conferring risk of psoriasis.
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Introduction
Psoriasis (Ps) is a relatively common, T cell-mediated,
inflammatory skin disease. Ps is typically manifested as thickened
scaly red plaques, characterized by epidermal hyperplasia,
increased vascularity in the dermis, and infiltration of inflamma-
tory cells into the dermis and epidermis [1,2,3]. Both genetics and
environment play a role in the etiology of Ps. Although its
pathogenic mechanism is not completely understood, investiga-
tions have strongly suggested that a susceptibility locus (PSORS1)
located within the human leukocyte antigen (HLA) class I region
on the short arm of chromosome 6, is the major genetic
determinant of psoriasis [4]. However, the exact location of the
PSORS1 gene had been controversial, due to the extended and
complicated linkage disequilibrium (LD) pattern of the region [5].
Early studies had indicated the existence of two major PSORS1
locations suggested by various fine mapping studies, one a region
,150 kb telomeric to HLA-C [6,7,8,9], harboring HCG27,
POU5F1, TCF19, CCHCR1 and CDSN, and the other HLA-C
itself or very close [10,11]. Recently, a combined sequencing and
haplotype mapping study found that within the 298 kb homolo-
gous region between the two proposed risk haplotypes, only HLA-
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translated protein, which at the same time conferred increased risk
of psoriasis, strongly suggesting that HLA-C is the Ps susceptibility
gene, and excluded the telomeric region [12]. Similarly, two other
family-based association studies, one in a white population and the
other in a Chinese population, confirmed the direct involvement
of HLA-C in psoriatic susceptibility [13,14]. In terms of specific risk
alleles, HLA-Cw*0602 has been consistently reported in numerous
populations, while the results have been controversial for HLA-
Cw*1203, showing modest positive association with psoriasis in
some studies [14,15], or no association [12,16], or even
significantly lower frequency in psoriasis patents than in controls
in others [17].
Located 85 kb centromeric to HLA-C, HLA-B has also
repeatedly exhibited association with psoriasis [18]. However,
the over-represented B serotypes, B*13 and B*57, are in tight LD
with HLA-Cw*0602 [19]; therefore, the association of HLA-B is
thought to be attributable to HLA-C, or the HLA-Cw*0602
harboring haplotypes 13.1 (Cw6-B13) and 57.1 (Cw6-B57), which
are named according to the B allele [20]. Likewise, genes located
farther from HLA-C at the centromeric end, including TNF-a
(tumor necrosis factor-alpha) [21,22], AGER (receptor of advanced
glycosylation end product-specific receptor) [23], HLA-DRB1,
HLA-DQA1 and HLA-DQB1 [24,25,26,27], have also been found
to be associated with psoriasis. Although some of these genes are as
far away from HLA-C as 1.38 megabases, the extended haplotype
pattern of the HLA region still makes it probable that the
association of these genes can be explained by LD with PSORS1,
i.e. HLA-C [11,28].
Other findings have suggested the existence of another
susceptibility gene in the major histocompatibility complex
(MHC) in addition to HLA-C. A study found that the octamer
transcription factor-3 (OTF3, also named POU5F1) B allele was
more prevalent in patients than in controls, even within the HLA-
Cw*0602-negative subset of samples [29]. Moreover, less than
25 kb from this gene, two single nucleotide polymorphisms (SNPs)
in the SEEK1 (PSORS1C1) gene retained association with psoriasis
upon stratification for HLA-Cw*0602 status (positive/negative)
[30]. However, these analyses did not consider HLA-Cw*1203, nor
did they account for the increased risk associated with HLA-
Cw*0602 homozygotes [31]. Thus, analyses conditional on HLA-
Cw*0602 only, or upon stratification on HLA-Cw*0602 positive/
negative status, may not completely remove the confounding by
HLA-C. Moreover, in contrast to the telomeric end, the
centromeric end of HLA-C has rarely been investigated conditional
on PSORS1.
Recently, within the framework of the Genetic Association
Information Network (GAIN) we performed a multi-center
collaborative genome-wide association study (GWAS), which
identified seven Ps susceptibility loci at a genome-wide level of
significance [32]. In this study, the most significantly associated
SNP was rs12191877 (p=3610
253), which is in strong LD with
HLA-Cw*0602 (r
2=0.63). In addition to this SNP, other MHC
SNPs that reached genome-wide significance spanned a 4 Mb
region, centering on HLA-C. Considering the widely scattered
physical locations of these associated SNPs, the density of immune
or inflammation related genes, and the above-mentioned multiple-
susceptibility-genes in this region hypothesized to be associated
with psoriasis, we searched for other psoriasis loci in the GAIN
dataset by examining the MHC region in more detail. First, we
used the CEPH phased data as a reference to derive a method of
determining the HLA-C genotypes based on the SNPs genotyped
as part of the GAIN projects [33]. This was followed by a stepwise
search for other susceptibility genes within the MHC region
conditional on the predicted HLA-Cw*0602. The findings from
these analyses were then replicated in an independent case-control
dataset from a Chinese population. These results demonstrate that
within the MHC region, there are at least two susceptibility loci for
Ps in addition to HLA-C.
Results
Imputation of HLA-Cw*0602 and HLA-Cw*1203 is accurate
Using the phased HLA and SNP genotypes contained in the
HapMap CEU panel and additional CEPH samples [33] as a
reference set, we imputed in each GAIN subject the HLA-
Cw*0602 and HLA-Cw*1203 genotypes, represented as the
predicted number of HLA-Cw*0602 or HLA-Cw*1203 alleles.
Since the SNP combinations used in the imputation were in
complete linkage disequilibrium with the HLA-C allele of interest
in the reference samples, the calculated uncertainties in the
imputation only arose from haplotype reconstruction. In all GAIN
samples, this uncertainty level was very low, indicated by the small
average difference between the imputed and the most likely
genotypes (0.002 and 0.0001 for HLA-Cw*0602 and HLA-
Cw*1203, respectively). In comparison with true HLA-C genotypes
obtained from direct sequencing in a subset of our samples
(n=420), there were no discrepancies observed for HLA-Cw*0602,
and only 2 for HLA-Cw*1203, leading to a discordant rate of less
than 0.5% (Table 1).
HLA-C is the major susceptibility gene within the MHC
In a logistic regression analysis, the imputed HLA-Cw*0602
allele was clearly associated with psoriasis. Both the significance
level and the magnitude of association were higher than those
observed for the most significant genotyped SNP, rs12191877
(p=8610
261 vs. p=3610
253; per allele OR=3.85 [3.25–4.55]
vs. OR=2.92 [2.54–3.37]) (Figure 1A). Another suggested risk
allele of HLA-C, HLA-Cw*1203 was significantly associated in
logistic regression adjusted for HLA-Cw*0602 (p=0.002,
OR=1.44 [1.14–1.81]), and in an analysis of the HLA-
Cw*0602-negative subset of samples (p=0.004, OR=1.44
[1.12–1.85]). Imputation of other HLA-C major alleles did not
show any association with psoriasis (data not shown). These
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Psoriasis (Ps) is a chronic inflammatory disease of the skin,
affecting approximately 2% of Europeans. The HLA-C gene,
located within the major histocompatibility complex
(MHC) region on chromosome 6, is the major genetic
determinant of psoriasis. However, multiple susceptibility
genes within MHC are also hypothesized. Recently, we
carried out a genome-wide association scan (GWAS) on
psoriasis with 1,359 patients and 1,400 healthy controls,
which identified seven psoriasis loci in the human genome
and confirmed the effect of HLA-C. This dataset contains
densely distributed genetic variations, single nucleotide
polymorphisms (SNPs), which were then further analyzed
in search for additional susceptibility genes within the
MHC region. Using the SNP data, we imputed in all
samples the HLA-C risk allele with high accuracy. Adjusting
for the HLA-C, two additional loci, one near C6orf10 and
one near HLA-B/MICA, have significant associations with
psoriasis, which were also observed in an independent
Han Chinese dataset, suggesting that within the MHC
there are at least three genes moderating susceptibility to
psoriasis.
Multiple Psoriasis Loci within the MHC
PLoS Genetics | www.plosgenetics.org 2 August 2009 | Volume 5 | Issue 8 | e1000606provide further confirmation that HLA-C is the major susceptibility
gene at the PSORS1 locus, and that HLA-Cw*0602 is the allele
associated with the highest risk.
C6orf10 is associated with psoriasis
To examine the association of other loci within the MHC region
with psoriasis, we applied logistic regression analyses to all other
genotyped SNPs in the MHC region (from 29.3 Mb to 33.7 Mb on
chromosome 6) adjusting for the imputed HLA-Cw*0602 genotype.
As expected, given the patterns of linkage disequilibrium across this
region, the levels of significance for association of the vast majority
of SNPs dropped dramatically (Figure 1B). The top SNP in the
unadjusted analyses, rs12191877, was no longer even nominally
significantly associated with Ps after adjustment for HLA-Cw*0602.
However, as seen in Figure 1B, we observed other SNPs that
remained significant after Bonferroni correction for multiple
testing. The SNP exhibiting the highest significance level,
rs2073048, is located at position 32.4 Mb within an open reading
frame, C6orf10, 27 kb telomeric to BTNL2 and 144 kb centro-
meric to NOTCH4. The minor allele (G) at this SNP had a
frequency of 15% in controls and was associated with an adjusted
odds ratio of 0.66 (95% confidence interval=[0.56–0.78],
p=2 610
26). To better understand the relationship between this
locus and HLA-C, we examined the effect of rs2073048 in a
stratified analysis in which strata were defined by carriage of HLA-
Cw*0602. The test of homogeneity of effect between strata showed
no evidence of heterogeneity (p=0.78). In the subset of samples
that does not contain an HLA-Cw*0602 allele, rs2073048 was still
significantly associated with psoriasis (OR=0.64 [0.53–0.78],
p=1 610
25). These results suggest that the association of this locus
with psoriasis is independent of HLA-Cw*0602.
HLA-B/MICA is associated with psoriasis
Another cluster of SNPs exhibiting significant p-values after
Bonferroni correction in Figure 1B were between HLA-B and
MICA. The most significant genotyped SNP of these, rs13437088,
is located 30 kb centromeric of HLA-B and 16 kb telomeric of
MICA. The minor allele of this SNP, T, had an allele frequency of
0.26 in controls, and was associated with an increased risk of
psoriasis (OR=1.32 [1.17–1.49], p=9610
26). In analyses
adjusted for HLA-Cw*0602 and rs2073048 (Figure 1C), the
association of this SNP was even stronger (OR=1.38 [1.22–
1.57], p=3610
27), suggesting that the observed association is not
due to the LD with HLA-C or C6orf10.
In stratified analyses, there was no evidence of heterogeneity
when samples were stratified by HLA-Cw*0602, rs2073048, or
both (p=0.21, 0.26, and 0.58, respectively), showing that the
association of this locus is independent of HLA-C and of the
C6orf10 locus. When both of the newly identified putative
susceptibility loci and HLA-Cw*0602 were included in a logistic
regression model, each of them was significantly associated with
disease (p=3610
247,6 610
28 and 3610
27, for HLA-Cw*0602,
rs2073048 and rs13437088, respectively). Individuals carrying risk
genotypes at HLA-C, rs2073048 and rs13437088 were estimated to
be at a nine-fold increased risk of psoriasis compared to those
carrying low risk genotypes at all three loci (Table 2).
To assess whether HLA-B is responsible for the association of
rs13437088 with psoriasis risk,weimputedallHLA-Bserotypeswith
CEPH population frequencies .5%, as well as those serotypes
previously suggested to be associated with psoriasis (B*13, B*57 and
B*58). In a logistic regression analysis adjusted for HLA-Cw*0602
and rs2073048, two B serotypes (B*40 and B*57) were significantly
associated with psoriasis after Bonferroni correction for testing
multiple serotypes: One additional copy ofB*57 conferreda 1.7fold
elevated risk of disease, while B*40 was associated with a 40%
reduced risk. In individuals who did not carry HLA-Cw*0602,B * 4 0
remained significantly associated, while B*57 did not (Table 3).This
can be explained by the fact that B*57 is in tight LD with HLA-
Cw*0602, while B*40 is not in LD with HLA-Cw*0602 [19]. The
SNP rs13437088 was in high LD with B*57 (D’=1).
Replication of both loci in a Han Chinese population
To further confirm our findings of the two novel loci for
psoriasis within MHC, we tested them in an independent Han
Chinese sample that was included in another GWAS of psoriasis
[34]. Using the Han Chinese and Japanese HapMap data as a
reference, HLA-Cw*0602 genotypes were imputed using strategies
identical to those for the US sample. The predicted HLA-Cw*0602
allele was strongly associated with psoriasis (p=1610
2206), which
is quite comparable to the top SNP rs1265181 (p=2610
2208)
[34], whose genotypes were 99.6% identical to the predicted HLA-
Cw*0602, showing that HLA-Cw*0602 is the main susceptibility
allele within the PSORS1 region. On the other hand, HLA-
Cw*1203 was not associated with psoriasis in this population, after
adjustment for HLA-Cw*0602 or within the HLA-Cw*0602-
negative subset of samples.
To assess the two loci we observed in the US samples, we first
tested all genotyped SNPs within 100 kb of rs2073048, the first
locus we identified in the US study. The results indicated several
SNPs that were significantly associated, the most significant of
whichwastheSNPrs28732201,whichhada minorallelefrequency
of0.01, and odds ratioof2.85[1.81–4.50] witha p-value of7610
26
(Figure 1D). This SNP is located between C6orf10 and BTNL2,
Table 1. Comparison of the imputed HLA-C genotypes with
true genotypes.
HLA allele Imputed number of alleles 2/22 /++ /+
Cw*0602 0 247 0 0
0.805 0 1 0
0.955 0 1 0
0.991 0 2 0
0.992 0 1 0
0.993 0 3 0
0.994 0 1 0
0.995 0 1 0
0.996 0 7 0
0.997 0 6 0
0.998 0 4 0
0.999 0 13 0
1 0 115 0
1.992 0 0 1
1.998 0 0 3
2 003
Cw*1203 0 368 1 0
0.991 0 2 0
0.998 0 1 0
0.999 0 7 0
11 2 8 0
2 002
doi:10.1371/journal.pgen.1000606.t001
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PLoS Genetics | www.plosgenetics.org 3 August 2009 | Volume 5 | Issue 8 | e1000606Figure 1. Association of MHC SNPs with psoriasis. (A) Trend test of MHC SNPs in the GAIN dataset; (B) Logistic regression adjusted for HLA-
Cw*0602 in the GAIN dataset; (C) Logistic regression adjusted for HLA-Cw*0602 and rs2073048 in the GAIN dataset. (D) Logistic regression adjusted for
HLA-Cw*0602 in the Chinese dataset; (E) Logistic regression adjusted for HLA-Cw*0602 and rs28732201 in the Chinese dataset. The red lines indicate
the significance level by Bonferroni correction for the number of SNPs tested. The numbers of SNPs are 1593, 1593, 1591, 226, and 252 for (A–E),
respectively.
doi:10.1371/journal.pgen.1000606.g001
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downstream to the transcription end site of BTNL2. After
adjustment for both HLA-Cw*0602 and rs28732201, the locus of
HLA-B/MICA (within 100 kb of the SNP identified in the GAIN
dataset) also exhibited significant association, shown by the SNP
rs2442719 (OR=1.66 [1.36–2.03], p=8610
27, Figure 1E), locat-
ed only 1 kb from the telomeric end of HLA-B. When HLA-
Cw*0602, rs28732201 and rs2442719 were all included in a logistic
regression model, they all remained significantly associated
(p=2610
2102,1 610
25,a n d8 610
27, respectively).
We also imputed the B*40 and B*57 serotypes in these Chinese
samples and tested their associations with psoriasis controlling for
HLA-Cw*0602. Interestingly, similar to the US data, B*57 was
significantly associated with an increased risk of psoriasis
(OR=2.71 [1.81–4.06], p=1610
26), and B*40 with a reduced
risk (OR=0.74 [0.57–0.97], p=0.03). These associations re-
mained nominally significant when analyses were further adjusted
for the C6orf10 locus (OR=0.75 [0.58–0.98], p=0.04 for B*40
and OR=1.98 [1.05–3.73], p=0.03 for B*57).
Discussion
The association of HLA-C with psoriasis was first proposed as
early as 30 years ago [35]. However, until recently doubts
remained as to whether HLA-C or a nearby gene was the locus
responsible for the observed association. One of the difficulties
contributing to this is the fact that the HLA region has a
complicated and extended linkage disequilibrium pattern, while
harboring many immune response genes in high density. Recently,
sequencing and haplotype analyses studies have concluded that
HLA-C is the major risk determinant of psoriasis within the HLA
region, and HLA-Cw*0602 is the main risk allele. However, one
immediate question arose: is HLA-C the only susceptibility gene in
this region? This question turns out to be challenging because any
other putative psoriasis predisposing genes would have a weaker
effect than HLA-Cw*0602, and the analyses would be complicated
by potential linkage disequilibrium with HLA-C. To control for the
effects of HLA-C, it would be optimal to use the HLA-C genotype
per se; however, in a large multi-center study such as the present
one, molecular typing of the HLA alleles would not be readily
available. In this paper, we used the CEPH phased data which
contains the phased alleles at HLA-A, -B, -C –DR and –DQ as well
as thousands of SNPs in this region as a reference sample to
identify SNPs that can accurately predict the HLA-C alleles. These
genotypes can then be used to perform analyses to search for other
susceptibility genes. As our validation study illustrated, we were
able to accurately predict the HLA-C alleles in the GAIN samples,
in spite of it being composed of a diverse (though all white) mixture
Table 2. Psoriasis risk conferred by the three MHC loci in the GAIN dataset.
Cw*0602 rs13437088
a rs2073048
b Case (%) Control (%) O.R. [95%CI] p-value
- - - 54 (4) 146 (10) 1 Ref.
-- + 306 (23) 518 (37) 1.60 [1.13–2.25] 0.007
- + - 86 (6) 189 (14) 1.23 [0.82–1.84] 0.31
- ++ 277 (20) 308 (22) 2.43 [1.71–3.46] 5610
27
+ - - 25 (2) 19 (1) 3.56 [1.81–6.97] 0.0001
+ - + 192 (14) 86 (6) 6.04 [4.04–9.03] 1610
219
++ - 75 (6) 28 (2) 7.24 [4.24–12.4] 2610
214
++ + 342 (25) 104 (7) 8.89 [6.07–13.0] 5610
233
a‘+’ denotes genotype CT/TT (presence of the risk allele T);
b‘+’ denotes genotype AA (absence of the protective allele G).
doi:10.1371/journal.pgen.1000606.t002
Table 3. Association of major HLA-B serotypes with psoriasis in the GAIN dataset.
HLA-B serotype Adjusted O.R. [95%CI]
a Adjusted p-value
a Cw6 -/- O.R. [95%CI]
b Cw6 -/- p-value
b
7 0.90 [0.75–1.07] 0.24 0.91 [0.74–1.10] 0.33
8 1.13 [0.93–1.37] 0.23 1.13 [0.91–1.38] 0.27
13 1.16 [0.83–1.64] 0.38 1.26 [0.47–3.37] 0.64
15 1.01 [0.81–1.26] 0.91 1.09 [0.86–1.39] 0.48
18 0.96 [0.71–1.30] 0.80 0.93 [0.68–1.29] 0.67
35 0.91 [0.74–1.13] 0.40 0.90 [0.71–1.14] 0.38
40 0.61 [0.47–0.79] 0.0002
c 0.65 [0.49–0.87] 0.003
c
44 0.85 [0.71–1.03] 0.09 0.77 [0.62–0.95] 0.01
57 1.66 [1.25–2.19] 0.0004
c 2.92 [1.36–6.25] 0.006
58 1.22 [0.54–2.73] 0.64 1.09 [0.44–2.71] 0.85
aAdjusted for HLA-Cw*0602 and rs2073048;
bIn the HLA-Cw*0602-negative subset of samples, adjusted for rs2073048;
cSignificant after Bonferroni correction (p,0.005).
doi:10.1371/journal.pgen.1000606.t003
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the present study, others have found similar utility of this approach
across European-derived populations. For example, a validation
assessment of the imputation method carried out on Dutch, UK,
Spanish, and Italian samples showed high sensitivity and specificity
in imputing DQA1, DQB1 and DRB1 alleles [33,36]. Moreover, the
genomic control [37] parameter of our samples was 1.03,
suggesting that population stratification has negligible impact on
our association results [32].
Through this imputation, we confirmed that HLA-Cw*0602 is
the major psoriasis risk determinant within the HLA region, which
has a much stronger association with psoriasis than the most
significantly associated SNP, rs12191877. This has reinforced the
importance of using HLA-C risk allele per se in the analyses of
MHC, since adjusting for the surrogate SNP cannot fully control
for HLA-C. Our analyses also provided further evidence that HLA-
Cw*1203 is associated with psoriasis, although it is not clear
whether HLA-Cw*1203 is a risk allele itself, or is in LD with the
risk allele of another susceptibility gene near HLA-C. On the other
hand, HLA-Cw*1203 was not associated with psoriasis in the Han
Chinese after adjustment for HLA-Cw*0602. These may imply
that HLA-Cw*1203 does not confer risk to psoriasis; the
discrepancies in its association with psoriasis in different studies
may be due to the different LD patterns among populations.
To search for additional loci for psoriasis in the MHC region,
we conducted logistic regression analyses adjusting for the imputed
HLA-Cw*0602, and identified two loci within 1.2 Mb of HLA-C,
one around the C6orf10 gene, and one between HLA-B and MICA.
Both of these loci were significantly associated with disease risk
after Bonferroni correction for the number of SNPs considered in
the analyses. Furthermore, data analyses demonstrate that they are
not simply reflecting linkage disequilibrium with HLA-C, since 1)
the associations are not secondary to HLA-Cw*0602 as shown in
the analyses adjusted for HLA-Cw*0602 or within the HLA-
Cw*0602-negative subset of samples, 2) further adjustment for
HLA-Cw*1203 in analyses did not substantially change our results,
and 3) no other HLA-C major allele showed association with
psoriasis in our data. More importantly, both associated loci were
replicated in an independent Han Chinese dataset after adjust-
ment for HLA-Cw*0602, even though the LD patterns in Chinese
are quite different from those in the GAIN dataset. All these
observations imply the existence of other psoriasis risk-determining
genes within the MHC. When the putative susceptibility loci and
HLA-Cw*0602 were included in a logistic regression model, they
all remained significantly associated with disease, showing that
these loci are not attributable to each other; therefore, within the
MHC there are at least three genes conferring risk of psoriasis.
The first locus we identified is located 1.1 Mb centromeric of
HLA-C, indicated by the SNP rs2073048. It is noteworthy that in
our previous paper, using a forward selection technique, we also
found some evidence of another SNP (rs2022544) close to this
locus that was associated with Ps, but this study did not control for
the HLA-C risk allele, but rather for its surrogate SNP [32],
rendering the results subject to residual association of HLA-C. The
SNP rs2073048 is located within the 4
th intron of an open reading
frame C6orf10, 27 kb telemetric to BTNL2 and 144 kb centromeric
to NOTCH4. There have been previous reports of association of
psoriasis with AGER, which is 183 kb telomeric of rs2073048, and
with HLA-DRB1 that is 211 kb centromeric of rs2073048. In the
present study, analyses of imputed serotypes of HLA-DRB1 did not
support the involvement of HLA-DRB1 in disease pathogenesis
(data not shown). Furthermore, as noted before, there is a
recombination hot spot centromeric to NOTCH4 [38], reducing
the possibility that the association at this locus is attributable to
those genes located telomeric to the recombination hot spot
(NOTCH4, AGER, etc.), although they still cannot be completely
excluded. Thus, C6orf10 and BTNL2 are better candidate genes for
this locus. The most associated SNP found in the GAIN dataset
(rs2073048) after correction for HLA-Cw*0602 is located within
C6orf10, and the SNP found in the Chinese dataset (rs28732201) is
close to the transcription start site of C6orf10; therefore, C6orf10 is
one of the most important candidate genes at this locus. It has
been observed that the transcription of C6orf10 in keratinocytes
can be triggered by TNF-a (Gene Expression Omnibus dataset
number: GDS1289) [39], an important proinflammatory cytokine
in the pathogenesis of psoriasis, although the function of the
C6orf10 product is not known. Nevertheless, other genes cannot be
excluded; more haplotype and sequencing analyses will be
required to pinpoint the risk-conferring variants at this locus.
The second locus we observed after adjustment for HLA-C and
C6orf10 is between HLA-B and MICA, located 117 kb centromeric
to HLA-C, suggesting the potential association of HLA-B or MICA
with psoriasis risk. In the Chinese samples, this locus was also
indicated by logistic regression analyses adjusted for HLA-C and
C6orf10, by a SNP located only 1 kb telomeric to HLA-B. More
importantly, although the linkage disequilibrium patterns and the
HLA-B tagging SNPs were different between Chinese and white
populations, the same HLA-B serotypes were associated with
psoriasis: B*57 with an increased risk and B*40 with a reduced
risk. These are suggestive of the involvement of HLA-B in psoriasis
etiology. The role of HLA-B in psoriasis immuno-pathogenesis
might be similar to that of HLA-C, which has been shown to bind
peptide motifs that are shared between the streptococcal M proteins
and the wound-healing-associated keratins k16 and k17, thereby
clonally expanding the pool of skin-directed autoreactive CD8+ T
cells [40]. Another candidate gene for this locus, MICA, is a distant
homolog of the MHC class I protein. It can be induced by cellular
or metabolic stress in the epithelia, acting as ligands for the
activatory T-cell receptor, NKG2D. In psoriasis, it has been shown
that MICA is down-regulated in lesional skin compared with non-
lesional skin (p=0.007, Gene Expression Omnibus dataset number:
GDS2518) [41]. The under-expression of the MICA protein might
allow the unwanted cells to escape the cytolysis by NK or CD8+ T-
cells, resulting in keratinocyte proliferation and the enhanced
inflammationinherenttolesionsofpsoriasis.Othergeneswithinthis
region still cannot be excluded by our analyses; more detailed
studies of HLA-B serotypes and MHC haplotypes are required to
further elucidate the association of this locus with psoriasis.
ThestudyofassociationsintheMHCregionisnotoriouslydifficult
due to the presence of many genes involved in immune and
inflammatory processes as well as the extensive and complex patterns
of linkage disequilibrium. Our use of a genome-wide panel of SNPs
that included nearly 2000 SNPs within the MHC, a validated
prediction method to determine withh i g hp r o b a b i l i t yt h ep r e s e n c eo f
known HLA-C risk alleles for Ps, and a large sample of psoriasis cases
and controls allowed us to begin to tease out different effects on
psoriasis risk within the MHC region. Our discoveries are replicated
in independent samples from another race, reinforcing the evidence
of our findings. In combination with the loci reported in our previous
work [32,42], and those yet to be identified from large-scale
replication studies of thousands of loci arising from our own and
other genome-wide association studies, we anticipate that substantial
progress will be made in the coming months in explaining the genetic
basis of psoriasis. Perhaps more relevantly, we anticipate that some of
the genes identified will prove to be attractive therapeutic targets,
leading to improved treatment for this disease.
In conclusion, we provide evidence that two loci within the
HLA region in addition to HLA-C, one near C6orf10 and one near
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within MHC there are at least three genes moderating
susceptibility to psoriasis. However we fully recognize that
additional studies including re-sequencing and detailed haplotype
analysis will be required to elucidate the causal variants.
Materials and Methods
Subject recruitment
The initial genome wide association scan involved 1409
psoriasis patients and 1436 controls recruited from the University
of Utah, the University of Michigan, and the Washington
University at St. Louis, USA. All cases and controls were of
European descent. Informed consent was obtained from each
participant. In total, 1359 cases and 1400 controls with 447,249
SNP genotypes passed the quality control process. The average
age at onset of psoriasis was 24.3 years with the majority of
patients (1127, 82.9%) developing psoriasis before age 40.
Additional details on subject characteristics and recruitment can
be found in Nair et al [32].
The samples in the replication analyses were 1139 cases and
1132 controls used in the initial GWAS of psoriasis conducted at
the Anhui Medical University, Hefei city, Anhui province, China.
These samples were recruited from Han Chinese populations by
multiple hospitals in China. More details about the studied
samples are described elsewhere [34]. The local institutional
review board at each site approved the study protocol.
HLA-C, HLA-B, and HLA-DRB1 genotype imputation
We used the phased HLA and SNP genotypes contained in the
HapMap CEU panel (30 trios) and an additional set of 90 CEPH
samples [33] to search for SNP combinations in linkage
disequilibrium with specific HLA alleles, using an approach similar
to that taken by de Bakker et al [33], except that whenever possible,
a combination of 3 to 4 SNPs was used. In each of our GAIN
samples, we inferred the haplotypes of these chosen SNPs and the
corresponding haplotype probabilities using the PHASE program
version 2.1 [43,44], for case and control populations separately as
suggested by Mensah et al [45]. The imputed HLA genotype
containing an allele of interest was represented as the estimated
number of copies of each specific allele, and was calculated by
summing the probability of having that allele given a specific
haplotype, weighted by the corresponding haplotype probability:
g~
X
i
pA i1 hi1 j ðÞ zpA i2 hi2 j ðÞ ½  |ph i ðÞ
where g is the imputed number of HLA alleles, AiN denotes an event
that the haplotype iN contains the HLA allele of interest, hiN is one of
the two haplotypes of the haplotype assignment i from PHASE, and
p(hi) is the haplotype probability. The p(AiN|hi) was directly obtained
from the reference samples, and the p(hi) was calculated by the
PHASE program. Thus, the uncertainties from the incomplete LD
between the haplotype and the HLA allele, and from the haplotype
reconstruction, were both integrated into the imputation; although
notalluncertaintycanbeestimated duetothe relativelysmallsizeof
theHapMapandCEPHsample.Togainmorepowerinassociation
test, we minimized the overall uncertainty level (estimated by the
averaged difference between the imputed and the most likely
genotype), by maximizing the LD between the haplotype and the
HLA allele, and by maximizing the haplotype probabilities by
inclusion of nearby SNPs in low LD with the HLA imputing SNPs
in haplotype reconstruction. These additional SNPs were selected
by the HAPLOVIEW program [46], with a threshold of r
2,0.1.
For better imputation accuracies, a more stringent quality control
strategy than the GWAS was applied, where those SNPs with
,99.5% genotype call rates, or with evidence for departure from
Hardy-Weinberg equilibrium at p,0.001 among controls, were not
considered. To validate the imputed HLA-C genotypes, a sub-
sample of 420 Utah psoriasis patients were genotyped using direct
sequencing at Atria Inc. (South San Francisco, CA).
Association analyses
e conducted trend tests to assess the association between SNPs
and psoriasis, using the PLINK program [47]. To examine the
association of a specific HLA allele with psoriasis, we used logistic
regression analysis on the imputed HLA genotype, weighted
according to genotype probabilities as suggested by Mensah et al
[45], i.e., in our analyses of HLA, we used the imputed number of
alleles (real number between 0 and 2), rather than the most likely
number of alleles (0, 1 or 2) in logistic regression. To examine
other SNPs within the HLA region, logistic regression was
performed adjusted for HLA-C and associated SNP genotype,
using the PLINK program [47]. Averaged odds ratio and the
corresponding 95% confidence intervals for each additional
number of minor allele of the studied SNP were calculated.
Linkage disequilibrium plots and recombination rate plots were
produced using the HapMap phase II data [48] by a C++ program
written by the authors.
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